# US 2013/0252956 A1 · Methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252956 A1
- Document ID: US20130252956A1
- Status: Published application
- Kind: A1
- Application number: 13/988,561
- Filed: 2011-11-21
- Published: 2013-09-26
- Earliest claimed: 2010-11-22
- Inventors: Howard Kallender; Lone Ottesen
- Web page: https://patentgrep.com/patent/US20130252956A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating a human having heptocellular carcinoma comprising administering to the human a therapeutically effective amount of Compound A: or a pharmaceutically acceptable salt thereof, wherein the human has a complete response or partial response.

## Claims

### Claim 1

A method of treating a human having heptocellular carcinoma comprising administering to said human a therapeutically effective amount of Compound A:
or a pharmaceutically acceptable salt thereof, wherein said human has a complete response or partial response.

### Claim 2 (depends on 1)

The method of claim 1, wherein said human has complete response.

### Claim 3 (depends on 1)

The method of claim 1, wherein said human has partial response.

### Claim 4 (depends on 1)

The method of claim 1, wherein said complete or partial response is measured by a modified RECIST criteria.

### Claim 5 (depends on 1)

The method of claim 1, wherein said complete or partial response is measured by RECIST 1.0 criteria.

### Claim 6 (depends on 1)

The method of claim 1, wherein Compound A is administered as a free base.

### Claim 7 (depends on 1)

The method of claim 1, wherein Compound A is administered at a dose of at least 7.5 mg daily.

### Claim 8 (depends on 1)

The method of claim 1, wherein Compound A is administered at a dose of at least about 30 mg daily.

### Claim 9 (depends on 1)

The method of claim 1, wherein said hepatocellular carcinoma is unresectable or metastatic.

### Claim 10 (depends on 1)

The method of claim 1, wherein said human has not previously received another multiple receptor tyrosine kinase inhibitor.

### Claim 11 (depends on 1)

The method of claim 1, wherein said Compound A is administered as monotherapy.

### Claim 12

A method of treating a human in need thereof comprising administering to said human 30 mg and/or 45 mg of Compound A, wherein said human has hepatocellular cancer.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

A method inducing a complete response in a human comprising administering to said human a therapeutically effective amount of Compound A:
or a pharmaceutically acceptable salt thereof, wherein said human has heptocellular carcinoma.
